UPLOAD Filing
Aspire Biopharma Holdings, Inc.
Date: Sept. 24, 2025 · CIK: 0001847345 · Accession: 0000000000-25-010426
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-290359
Letter
Re: Aspire Biopharma Holdings, Inc. Registration Statement on Form S-1 Filed September 18, 2025 File No. 333-290359 Dear Kraig T. Higginson:
September 24, 2025
Kraig T. Higginson Chairman, Chief Executive Officer Aspire Biopharma Holdings, Inc. 23150 Fashion Drive, Suite 232 Estero, FL 33928
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Arthur S. Marcus, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> September 24, 2025 Kraig T. Higginson Chairman, Chief Executive Officer Aspire Biopharma Holdings, Inc. 23150 Fashion Drive, Suite 232 Estero, FL 33928 Re: Aspire Biopharma Holdings, Inc. Registration Statement on Form S-1 Filed September 18, 2025 File No. 333-290359 Dear Kraig T. Higginson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Arthur S. Marcus, Esq. </TEXT> </DOCUMENT>